Since the discovery of the RET receptor tyrosine kinase in 1985, alterations of this protein have been found in diverse thyroid cancer subtypes. RET gene rearrangements are observed in papillary thyroid carcinoma, which result in RET fusion products. By contrast, single amino acid substitutions and small insertions and/or deletions are typical of hereditary and sporadic medullary thyroid carcinoma. RET rearrangements and mutations of extracellular cysteines facilitate dimerization and kinase activation, whereas mutations in the RET kinase coding domain drive dimerization-independent kinase activation. Thus, RET kinase inhibition is an attractive therapeutic target in patients with RET alterations. This approach was initially achieved using multikinase inhibitors, which affect multiple deregulated pathways that include RET kinase. In clinical practice, use of multikinase inhibitors in patients with advanced thyroid cancer resulted in therapeutic efficacy, which was associated with frequent and sometimes severe adverse effects. However, remarkable progress has been achieved with the identification of novel potent and selective RET kinase inhibitors for the treatment of advanced thyroid cancer. Although expanded clinical validation in future trials is needed, the sustained antitumoural activity and the improved safety profile of these novel compounds is opening a new exciting era in precision oncology for RET-driven cancers.
Alterations in RET are frequent key events in thyroid tumorigenesis.
Single amino acid mutations and small deletions and/or insertions, or gene fusions involving RET represent oncogenic driving forces in medullary thyroid carcinoma and papillary thyroid carcinoma, respectively.
Multitargeted tyrosine kinase inhibitors (TKIs) currently represent the mainstay of treatment for advanced radioiodine-refractory thyroid cancer and advanced medullary thyroid carcinoma.
Novel RET TKIs that target RET kinase potently with increased selectivity might be effective and better tolerated than the drugs already in clinical practice for the treatment of advanced thyroid cancer.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schlumberger, M., Carlomagno, F., Baudin, E., Bidart, J. M. & Santoro, M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat. Clin. Pract. Endocrinol. Metab. 4, 22–32 (2008).
Markham, A. Selpercatinib: first approval. Drugs 80, 1119–1124 (2020).
[No authors listed] FDA approves selpercatinib; pralsetinib may soon follow. Cancer Discov. 10, OF1 (2020).
Takahashi, M., Ritz, J. & Cooper, G. M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42, 581–588 (1985). This article describes the first isolation of RET as well as the first demonstration of its oncogenic activity.
Ishizaka, Y. et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4, 1519–1521 (1989).
Simpson, N. E. et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 328, 528–530 (1987).
Takahashi, M., Buma, Y. & Hiai, H. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 4, 805–806 (1989).
Grieco, M. et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60, 557–563 (1990).
Mulligan, L. M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458–460 (1993).
Kohno, T. et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18, 375–377 (2012).
Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382–384 (2012).
Takeuchi, K. et al. RET, ROS1 and ALK fusions in lung cancer. Nat. Med. 18, 378–381 (2012).
Mulligan, L. M. 65 years of the double helix: exploiting insights on the RET receptor for personalized cancer medicine. Endocr. Relat. Cancer 25, T189–T200 (2018).
Plaza-Menacho, I. Structure and function of RET in multiple endocrine neoplasia type 2. Endocr. Relat. Cancer 25, T79–T90 (2018).
Subbiah, V. & Cote, G. J. Advances in targeting RET-dependent cancers. Cancer Discov. 10, 498–505 (2020).
Knowles, P. P. et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J. Biol. Chem. 281, 33577–33587 (2006). This article describes the crystal structure of the RET kinase domain as well as of it in complex with ATP-competitive kinase inhibitors.
Plaza-Menacho, I. et al. Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans. Mol. Cell 53, 738–751 (2014).
Redaelli, S., Plaza-Menacho, I. & Mologni, L. Novel targeted therapeutics for MEN2. Endocr. Relat. Cancer 25, T53–T68 (2018).
Ibanez, C. F. Structure and physiology of the RET receptor tyrosine kinase. Cold Spring Harb. Perspect. Biol. 5, a009134 (2013).
Meng, X. et al. Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. Science 287, 1489–1493 (2000).
Lindfors, P. H., Lindahl, M., Rossi, J., Saarma, M. & Airaksinen, M. S. Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor α4 impairs thyroid calcitonin production in young mice. Endocrinology 147, 2237–2244 (2006).
Canibano, C. et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 26, 2015–2028 (2007).
Veiga-Fernandes, H. et al. Tyrosine kinase receptor RET is a key regulator of Peyer’s patch organogenesis. Nature 446, 547–551 (2007).
Ohgami, N. et al. c-Ret-mediated hearing loss in mice with Hirschsprung disease. Proc. Natl Acad. Sci. USA 107, 13051–13056 (2010).
Fonseca-Pereira, D. et al. The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function. Nature 514, 98–101 (2014).
Goodman, K. M. et al. RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association. Cell Rep. 8, 1894–1904 (2014).
Breit, S. N., Tsai, V. W. & Brown, D. A. Targeting obesity and cachexia: identification of the GFRAL receptor-MIC-1/GDF15 pathway. Trends Mol. Med. 23, 1065–1067 (2017).
Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018).
Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158–1166 (2017).
Bordeaux, M. C. et al. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J. 19, 4056–4063 (2000).
Plaza-Menacho, I. et al. RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements. Cell Rep. 17, 3319–3332 (2016).
Heanue, T. A. & Pachnis, V. Enteric nervous system development and Hirschsprung’s disease: advances in genetic and stem cell studies. Nat. Rev. Neurosci. 8, 466–479 (2007).
Amiel, J. et al. Hirschsprung disease, associated syndromes and genetics: a review. J. Med. Genet. 45, 1–14 (2008).
Carlomagno, F. et al. Molecular heterogeneity of RET loss of function in Hirschsprung’s disease. EMBO J. 15, 2717–2725 (1996).
Mulligan, L. M. GDNF and the RET receptor in cancer: new insights and therapeutic potential. Front. Physiol. 9, 1873 (2018).
Wells, S. A. Jr., Pacini, F., Robinson, B. G. & Santoro, M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J. Clin. Endocrinol. Metab. 98, 3149–3164 (2013).
Landsvater, R. M. et al. The clinical implications of a positive calcitonin test for C-cell hyperplasia in genetically unaffected members of an MEN2A kindred. Am. J. Hum. Genet. 52, 335–342 (1993).
Machens, A. & Dralle, H. Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 33, 101274 (2019).
Mathiesen, J. S. et al. Incidence and prevalence of sporadic and hereditary MTC in Denmark 1960-2014: a nationwide study. Endocr. Connect. 7, 829–839 (2018).
Eng, C. et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin. Endocrinol. 43, 123–127 (1995).
Romei, C. et al. Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid 22, 476–481 (2012).
Elisei, R. et al. Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes 10, 698 (2019).
Wells, S. A. Jr. Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors. Endocr. Relat. Cancer 25, T1–T13 (2018).
Eng, C. et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis. JAMA 276, 1575–1579 (1996).
Mulligan, L. M. et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet. 6, 70–74 (1994).
Santoro, M. et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267, 381–383 (1995).
Kloos, R. T. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565–612 (2009).
Romei, C. et al. RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin. Endocrinol. 74, 241–247 (2011).
Castinetti, F., Moley, J., Mulligan, L. & Waguespack, S. G. A comprehensive review on MEN2B. Endocr. Relat. Cancer 25, T29–T39 (2018).
Castinetti, F. et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol. 7, 213–220 (2019).
Gujral, T. S., Singh, V. K., Jia, Z. & Mulligan, L. M. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res. 66, 10741–10749 (2006).
Miyauchi, A. et al. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn. J. Cancer Res. 90, 1–5 (1999).
Menko, F. H. et al. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J. Clin. Endocrinol. Metab. 87, 393–397 (2002).
Cranston, A. N. et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res. 66, 10179–10187 (2006).
Nakao, K. T. et al. Novel tandem germline RET proto-oncogene mutations in a patient with multiple endocrine neoplasia type 2B: report of a case and a literature review of tandem RET mutations with in silico analysis. Head Neck 35, E363–E368 (2013).
Ciampi, R. et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 20, 324–336 (2019).
Heilmann, A. M. et al. Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. Oncology 90, 339–346 (2016).
Elisei, R. et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 93, 682–687 (2008).
Grubbs, E. G. et al. RET fusion as a novel driver of medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 100, 788–793 (2015).
Moura, M. M., Cavaco, B. M. & Leite, V. RAS proto-oncogene in medullary thyroid carcinoma. Endocr. Relat. Cancer 22, R235–R252 (2015).
Agrawal, N. et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J. Clin. Endocrinol. Metab. 98, E364–E369 (2013).
Boichard, A. et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J. Clin. Endocrinol. Metab. 97, E2031–E2035 (2012).
Santoro, M., Moccia, M., Federico, G. & Carlomagno, F. RET gene fusions in malignancies of the thyroid and other tissues. Genes 11, 424 (2020).
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014). This article describes the comprehensive characterization of the genetic lesions associated with human PTC and the identification of molecularly defined PTC subgroups.
Caudill, C. M., Zhu, Z., Ciampi, R., Stringer, J. R. & Nikiforov, Y. E. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to γ-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J. Clin. Endocrinol. Metab. 90, 2364–2369 (2005).
Alzahrani, A. S. et al. Genetic alterations in pediatric thyroid cancer using a comprehensive childhood cancer gene panel. J. Clin. Endocrinol. Metab. 105, 3324–3334 (2020).
Pekova, B. et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 30, 1771–1780 (2020).
Dias-Santagata, D. et al. Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma. Thyroid 30, 1384–1389 (2020).
Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052–1066 (2016).
Drilon, A., Hu, Z. I., Lai, G. G. Y. & Tan, D. S. W. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat. Rev. Clin. Oncol. 15, 151–167 (2018).
Paratala, B. S. et al. RET rearrangements are actionable alterations in breast cancer. Nat. Commun. 9, 4821 (2018).
Pietrantonio, F. et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann. Oncol. 29, 1394–1401 (2018).
Wiesner, T. et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat. Commun. 5, 3116 (2014).
Antonescu, C. R. et al. Spindle cell tumors with RET gene fusions exhibit a morphologic spectrum akin to tumors with NTRK gene fusions. Am. J. Surg. Pathol. 43, 1384–1391 (2019).
Guilmette, J., Dias-Santagata, D., Nose, V., Lennerz, J. K. & Sadow, P. M. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum. Pathol. 83, 50–58 (2019).
Skalova, A. et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is “intraductal” correct? Am. J. Surg. Pathol. 43, 1303–1313 (2019).
Ballerini, P. et al. RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation. Leukemia 26, 2384–2389 (2012).
Mizukami, T. et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma. J. Thorac. Oncol. 9, 622–630 (2014).
Ricarte-Filho, J. C. et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J. Clin. Invest. 123, 4935–4944 (2013). This article describes the systematic characterization of gene fusion events driving the formation of post-Chernobyl PTC.
Ameziane-El-Hassani, R. et al. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res. 70, 4123–4132 (2010).
Wells, S. A. Jr. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134–141 (2012). This article describes the clinical study that led to the registration of the first targeted therapy for advanced MTC.
Subbiah, V., Yang, D., Velcheti, V., Drilon, A. & Meric-Bernstam, F. State-of-the-art strategies for targeting RET-dependent cancers. J. Clin. Oncol. 38, 1209–1221 (2020).
Wirth, L. J. et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383, 825–835 (2020). This article describes the prospective trial that led to the first registration of a RET-specific TKI in patients with advanced thyroid carcinoma who have a RET mutation.
Drilon, A. et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 383, 813–824 (2020).
Kurzrock, R. Selpercatinib aimed at RET-altered cancers. N. Engl. J. Med. 383, 868–869 (2020).
Subbiah, V. et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann. Oncol. 29, 1869–1876 (2018).
Carlomagno, F. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62, 7284–7290 (2002).
Zhao, Z. et al. Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9, 1230–1241 (2014).
De Falco, V., Carlomagno, F., Li, H. Y. & Santoro, M. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 31, 307–318 (2017).
Frett, B. et al. Fragment-based discovery of a dual pan-RET/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology. Angew. Chem. Int. Ed. Engl. 54, 8717–8721 (2015).
Subbiah, V. et al. Precision targeted therapy with BLU-667 for RET-driven cancers. Cancer Discov. 8, 836–849 (2018).
Schoffski, P. et al. A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer [abstract]. J. Clin. Oncol. 37 (Suppl. 15), TPS3162 (2019).
Drilon, A. et al. TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers [abstract 506P]. Ann. Oncol. 30 (Suppl. 5), v190–v191 (2019).
Carlomagno, F. et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23, 6056–6063 (2004).
Mologni, L., Redaelli, S., Morandi, A., Plaza-Menacho, I. & Gambacorti-Passerini, C. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol. Cell Endocrinol. 377, 1–6 (2013).
Carlomagno, F. et al. Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. Endocr. Relat. Cancer 16, 233–241 (2009).
Liu, X., Shen, T., Mooers, B. H. M., Hilberg, F. & Wu, J. Drug resistance profiles of mutations in the RET kinase domain. Br. J. Pharmacol. 175, 3504–3515 (2018).
Busaidy, N. L. et al. Emergence of V804M resistance gatekeeper mutation in sporadic medullary thyroid carcinoma patients treated with TKI tyrosine kinase inhibitors. Thyroid 27, A166–A188 (2017).
Wirth, L. J. et al. Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in patients with RET-altered cancer. JCO Precis. Oncol. 3, 1–7 (2019).
Valerio, L. et al. V804M RET mutation and vandetanib response in metastatic medullary thyroid cancer. Eur. Thyroid J. 6, 23–118 (2017).
Solomon, B. J. et al. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J. Thorac. Oncol. 15, 541–549 (2020).
Huang, Q. et al. Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma. Mol. Cancer Ther. 15, 2521–2529 (2016).
Terzyan, S. S. et al. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J. Biol. Chem. 294, 10428–10437 (2019).
Nakaoku, T. et al. A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nat. Commun. 9, 625 (2018).
Rich, T. A. et al. Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations. Clin. Cancer Res. 25, 5832–5842 (2019).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014). This article describes the clinical study that led to the registration of the first targeted therapy for advanced DTC.
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015). This article describes the clinical study that led to the registration of lenvatinib therapy for advanced DTC.
Cabanillas, M. E. et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial. J. Clin. Oncol. 35, 3315–3321 (2017).
Bible, K. C. et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J. Clin. Endocrinol. Metab. 99, 1687–1693 (2014).
Ravaud, A. et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur. J. Cancer 76, 110–117 (2017).
Locati, L. D. et al. Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer 120, 2694–2703 (2014).
Elisei, R. et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31, 3639–3646 (2013). This article describes the clinical study that led to the registration of cabozantinib therapy for advanced MTC.
Kreissl, M. C. et al. Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer – post hoc analysis from the ZETA trial. J. Clin. Oncol. 38, 2773–2781 (2020).
Valerio, L. et al. Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response. Endocr. Relat. Cancer 27, 97–110 (2020).
Chougnet, C. N. et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 25, 386–391 (2015).
Schlumberger, M. et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin. Cancer Res. 22, 44–53 (2016).
Schlumberger, M. et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann. Oncol. 28, 2813–2819 (2017).
Verrienti, A. et al. RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocr. Relat. Cancer 23, 665–676 (2016).
Akeno-Stuart, N. et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 67, 6956–6964 (2007).
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. & Hurria, A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692–2699 (2017).
Subbiah, V. et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+solid tumors. J. Clin. Oncol. 38, 109 (2020).
Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A. & Ryan, A. J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert. Opin. Investig. Drugs 16, 239–249 (2007).
Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298–2308 (2011).
Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129–3140 (2008).
Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835–844 (2006).
Plaza-Menacho, I. et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 282, 29230–29240 (2007).
Matsui, J. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 14, 5459–5465 (2008).
Matsui, J. et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 122, 664–671 (2008).
Okamoto, K. et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 340, 97–103 (2013).
Keegan, M., Wilcoxen, K. & Ho, P. T. BOS172738: a novel highly potent and selective RET kinase inhibitor in phase 1 clinical development [abstract]. Cancer Res. 79 (Suppl. 13), 2199 (2019).
El-Gebali, S. et al. The Pfam protein families database in 2019. Nucleic Acids Res. 47, D427–D432 (2019).
Wells, S. A. Jr. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015). Comprehensive guidelines for all aspects of the diagnosis, classification and management of MTC.
Li, A. Y. et al. RET fusions in solid tumors. Cancer Treat. Rev. 81, 101911 (2019).
Cote, G. J. et al. Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 102, 3591–3599 (2017).
The authors acknowledge the support of a grant under the European Union’s Horizon 2020 Programme – EU FP7 contract Thyrage (grant number 666869) awarded to D.S. and the POR Campania FESR 2014-2020 “SATIN” grant awarded to M. Santoro. The authors gratefully acknowledge F. Carlomagno for critically reading the manuscript.
M. Santoro is inventor of patent WO/2015/187818. The other authors declare no competing interests.
Peer review information
Nature Reviews Endocrinology thanks L. Mulligan, C. Romei and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
cBioPortal for Cancer Genomics: https://www.cbioportal.org
National Cancer Institute Drug Dictionary: https://www.cancer.gov/publications/dictionaries/cancer-drug
Pfam database: https://pfam.xfam.org/
PubChem database: https://pubchem.ncbi.nlm.nih.gov/
About this article
Cite this article
Salvatore, D., Santoro, M. & Schlumberger, M. The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol 17, 296–306 (2021). https://doi.org/10.1038/s41574-021-00470-9